4th Quarter - Report

EISAI INC. for EISAI INC.

Firm
Client
Income
—
Expenses
$580,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S 1145, Patent Reform Act of 2007 HR 1908, Patent Reform Act of 2007

LobbyistCovered position, as disclosed
ROBERT FEENEY —
STEPHEN D MCMILLAN New —
PETER NORMAN New —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1908 (110th)

Taxation/Internal Revenue Code TAX

Extension of the R&D Tax Credit

LobbyistCovered position, as disclosed
ROBERT FEENEY —
STEPHEN D MCMILLAN New —
PETER NORMAN New —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Medical/Disease Research/Clinical Labs MED

Comparative Effectiveness Alzheimer's awareness

LobbyistCovered position, as disclosed
ROBERT FEENEY —
STEPHEN D MCMILLAN New —
PETER NORMAN New —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

HR 5480, Medicare Funding Warning Response Act of 2008 HR 2606, 340B Program Improvement and Integrity Act of 2007, 340 drug price expansion HR 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions HR 3162, Children's Health and Medicare Protection Act of 2007 S 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion S 2029, Physician Payments Sunshine Act of 2007

LobbyistCovered position, as disclosed
ROBERT FEENEY —
STEPHEN D MCMILLAN New —
PETER NORMAN New —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 4 (110th), H.R. 2606 (110th), H.R. 5480 (110th), H.R. 3162 (110th)

Pharmacy PHA

HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S 1505, Affordable Biologics for Consumers Act, follow-on biologics S 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S 2029, Physician Payments Sunshine Act of 2007 S 595, Safe Internet Pharmacy Act of 2007 S 623, Access to Life-Saving Medicines Act, follow-on biologics HR 5629, Pathway for Biosimilars Act HR 5839, Safeguarding America's Pharmaceuticals Act

LobbyistCovered position, as disclosed
JENNIFER GRUBER —
STEPHEN D MCMILLAN New —
PETER NORMAN New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 1561 (110th), H.R. 1956 (110th), H.R. 5629 (110th), H.R. 1038 (110th), H.R. 5839 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.